Vertaling van "antioxidant and cardiovascular study " (Frans → Nederlands) :

35. Kang JH , Cook NR, Manson JE et al. Vitamin E, vitamin C, beta carotene, and cognitive function among women with or at risk of cardiovascular disease: The Women's Antioxidant and Cardiovascular Study.
35.Kang JH , Cook NR, Manson JE et al. Vitamin E, vitamin C, beta carotene, and cognitive function among women with or at risk of cardiovascular disease: The Women's Antioxidant and Cardiovascular Study.

- Richer S, Stiles W, Statkute L, Pulido J, Frankowski J, Rudy D, et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial).
- Lei LC, Chen O, Aldini G, Johnson E, Rasmussen H, Yasukazu Y et al. Supplementation with lutein or lutein plus green tea extracts does not change ocidative stress in adequately nourished older adults. J Nutr Biochem 2009, in press

Vivekananthan DP, Penn MS, Sapp SK et al. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials.
DOI: 10.1002/14651858.CD000254.pub3. Vivekananthan DP, Penn MS, Sapp SK et al. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials.

Hercberg S, Galan P, Preziosi P et al. The SU.VI. MAX Study: : a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and
verlaagt het risico op neurale buisdefecten bij de fœtus (Cochrane De-Regil: N=5, n=6.105: RR= 0,28 (95% BI 0,15-0,52)

10. Hercberg S, Galan P, Preziosi P et al. The SU.VI. MAX Study: : a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals.
10.Hercberg S, Galan P, Preziosi P et al. The SU.VI. MAX Study: : a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals.

Deux très grands essais cliniques, qui apporteront certainement plus de clarté à ce sujet sont encore en cours: ACCEPT-D (‘Aspirin and Simvastatin combination for Cardiovascular Events Prevention Trial in Diabetes’) et ASCEND (‘A Study of Cardiovascular Events in Diabetes’).
Twee zeer grote trials, die wellicht meer klaarheid over dit onderwerp zullen kunnen brengen zijn nog lopende: ACCEPT-D (Aspirin and Simvastatin combination for Cardiovascular Events Prevention Trial in Diabetes) en ASCEND (A Study of Cardiovascular Events in Diabetes).

Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies.
Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis.

Remerciements : Pour son aide précieuse relative à la méta-analyse : Cécile Dubois (KCE) Pour leur contribution au scoring des indicateurs : Raf Brouns et Matthieu Rutgers (Belgian Stroke Council) Pour la validation de la description de leur pays : Suède : Kiell Asplund (Chair, Risks Stroke Umea), Bo Norrving (Professor, Lund University-Steering committee member Riks stroke) Pays-Bas : Martien Limburg (Neuroloog, Flevoziekenhuis, Almere, Stichting Kennisnetwerk) Ecosse : Martin Dennis (Division of Clinical Neurosciences – Western General Hospital University of Edinburgh), Peter Langhorne (Professor of Stroke Care, Cardiovascular and Medical Sciences Division – University of Glasgow) Grande-Bretagne : Patrick Gompertz (Barts and the London Brain Attack Center, London), Gill Gluckie (Clinical lead, stroke, Guy’s and St. Thomas’ hospital, clinical lead, S/East London stroke network) France : France Woimant (Service de neurologie, hôpital Lariboisière, Paris – “Agence Régionale de Santé – Ilede-France”), Didier Leys (Département de neurologie, Hôpital universitaire de Lille) Allemagne : Peter Heuschmann (Neurologische klinik und poliklinik, Universitätsklinikum Würzburg) German Stroke Register Study Group), E. Bernd Ringelstein (Neurologische klinik und poliklinik, Universitätsklinikum Münster)
Acknowledgements: Voor haar waardevolle bijdrage in het gedeelte over meta-analyse: Cécile Dubois (KCE) Voor hun bijdrage bij het scoren van de indicatoren: Raf Brouns en Matthieu Rutgers (Belgian Stroke Council) Voor het valideren van de informatie over hun land: Zweden: Kiell Asplund (Chair, Risks Stroke Umeal), Bo Norrving (Professor, Lund University-Steering committee member Riks stroke) Nederland: Martien Limburg (Neuroloog, Flevoziekenhuis, Almere, Stichting Kennisnetwerk); Schotland: Martin Dennis (Division of Clinical Neurosciences – Western General Hospital University of Edinburgh), Peter Langhorne (Professor of Stroke Care, Cardiovascular and Medical Sciences Division – University of Glasgow) Verenigd Koninkrijk: Patrick Gompertz (Barts and the London Brain Attack Center, London), Gill Gluckie (Clinical lead, stroke, Guy’s and St. Thomas’ hospital, clinical lead, S/East London stroke network) Frankrijk: France Woimant (Service de neurologie, hôpital Lariboisière, Paris – “Agence Régionale de Santé – Ile-de-France”), Didier Leys (Département de neurologie, Hôpital universitaire de Lille) Duitsland: Peter Heuschmann (Neurologische klinik und poliklinik, Universitätsklinikum Würzburg) German Stroke Register Study Group), E. Bernd Ringelstein (Neurologische klinik und poliklinik, Universitätsklinikum Münster)

Baggish AL, Hutter AM, Jr., Wang F, Yared K, Weiner RB, Kupperman E et al. Cardiovascular screening in college athletes with and without electrocardiography: A cross-sectional study.
Baggish AL, Hutter AM, Jr., Wang F, Yared K, Weiner RB, Kupperman E et al. Cardiovascular screening in college athletes with and without electrocardiography: A crosssectional study.

Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).
Breast cancer and hormone-replacement therapy in the million Women Study.